

STATEMENT ON A NONPROPRIETARY NAME ADOPTED BY THE USAN COUNCIL:

USAN

ENOXAPARIN SODIUM

PRONUNCIATION

ee nox a pa' rin


THERAPEUTIC CLAIMS

antithrombotic intended for use in the treatment of deep vein thrombosis; prophylaxis of ischemic complications of unstable angina and non-Q-wave myocardial infarction, and treatment of acute deep vein thrombosis

CHEMICAL NAMES

- 1) enoxaparin sodium
- 2) sodium salt of a low-molecular weight heparin obtained by alkaline depolymerization of the benzyl ester of heparin from porcine mucosa.

STRUCTURAL FORMULA



R1 = H or SO₃Na and R2 = SO₃Na or COCH₃

R	X = 15 to 25%		n = 0 to 20
	100-X%	OH	n = 1 to 21

TRADEMARK(S)

Lovenox; Clexane

MANUFACTURER

Aventis

CODE DESIGNATION(S)

PK 10169; RP 54563

CAS REGISTRY NUMBER

679809-58-6

NOTE:

This Statement of Adoption contains revised chemical information and supercedes the Statement of Adoption on enoxaparin sodium, adopted September 28, 1994 (N94/72).